AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 131 min read$BBIO

Cook Jennifer E. sold $13.2M of BBIO

Cook Jennifer E. sold 148,589 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $88.54 ($84.00–$90.00, $13.16M total) across 2 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Jennifer E.
Published Jul 13, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed $13.16M open-market sale by a director can modestly influence sentiment, but it does not introduce new company fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without accompanying business or clinical news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total insider holdings beyond the post-transaction share count.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-13 for trades dated 2026-07-09

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Pharma director Jennifer E. Cook sold 148,589 shares in open-market trades under a 10b5-1 plan, totaling about $13.16M.

Expected impact

Likely limited, short-lived impact unless paired with other negative catalysts.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by a director; the article provides no new operational, clinical, or guidance information.

Market effects

Sector

Minimal, as this is company-specific insider transaction with no sector-wide regulatory or clinical signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Jennifer E. Cook

    Director who sold 148,589 shares under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 23
$BBIOMedAI 8/10

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Pharma (BBIO) said the FDA accepted its filing for encaleret, an oral investigational drug for autosomal dominant hypocalcemia type 1 (ADH1). A decision is expected by May 8, 2027. The company cited phase III CALIBRATE results and noted the FDA is not planning an advisory committee meeting. BBIO shares are up 8% YTD.

tradingview.com4 min
JUL 22
$BBIOMedAI 8/10

FDA accepts BridgeBio's NDA for encaleret to tr... | Pluang

BridgeBio Pharma said the FDA accepted its New Drug Application for encaleret, intended as a potential first treatment for autosomal dominant hypocalcemia type 1 (ADH1). The FDA target decision date is May 8, 2027. BridgeBio cited trial results showing efficacy and safety without routine calcium or vitamin D supplements, and is also studying pediatric ADH1 and chronic hypoparathyroidism.

pluang.com1 min
JUL 21
$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

biopharmadive.com7 min
JUL 10
$BBIOMedAI 8/10

BridgeBio stock jumps after rival heart drug fails key trial

BridgeBio (BBIO) shares rose 14.7% on July 9 after AstraZeneca and Ionis said their Wainua (eplontersen) failed the primary endpoint in a Phase 3 CARDIO-TTRansform trial for ATTR-CM. The study enrolled 1,432 patients. BridgeBio was trading around $89.86, adding about $2.2B in market value intraday.

yahoo.com4 min
JUL 9
$AZNHighAI 9/10

Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback

AstraZeneca and Ionis said their gene-silencing drug Wainua (eplontersen) failed the Phase 3 CARDIO-TTRansform trial in transthyretin-mediated amyloid cardiomyopathy. The study enrolled 1,432 patients over 140 weeks and did not significantly reduce cardiovascular deaths or recurrent events vs placebo. AstraZeneca shares fell about 9% and Ionis about 21%.

techtimes.com7 min